JNJ - Johnson & Johnson
| Previous Close | 123.45 |
| Open | 123.22 |
| Bid | 121.90 x 900 |
| Ask | 121.92 x 900 |
| Day's Range | 121.56 - 123.39 |
| 52 Week Range | 121.28 - 148.32 |
| Volume | 2,747,102 |
| Avg. Volume | 6,761,004 |
| Market Cap | 326.927B |
| Beta | 0.59 |
| PE Ratio (TTM) | 257.15 |
| EPS (TTM) | 0.47 |
| Earnings Date | Jul 17, 2018 |
| Forward Dividend & Yield | 3.36 (2.57%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 145.10 |
- InvestorPlace•1 hour ago
3 Pros, 3 Cons to Buying Medtronic PLC Stock
Can Medtronic PLC (NYSE:MDT) get its stock back in rhythm? Up until mid-2015, Medtronic stock was a star performer. It doubled from 2013 up to that point. Since then, Medtronic has seriously underperformed. MDT stock has spent the last three years in a tight trading range between $70 and $90 per share, while the rest of the market has launched further upward.
- InvestorPlace•2 hours ago
3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More
A month ago, Pfizer Inc. (NYSE:PFE) felt the sting of a somewhat surprising disappointment. Its biosimilar version of Herceptin, the popular breast cancer drug from Roche Holding AG (OTCMKTS:RHHBY), was rejected by the FDA.Biosimilar drugs are nearly-identical copies of a competitor’s product. It was a blow not just because Herceptin generated sales of more than $7 billion last year, but because it put the viability of Pfizer’s entire biosimilar program into question.
- Barrons.com•2 hours ago
Biopharma M&A: You Ain't Seen Nothing Yet
Barron's has previously discussed how mergers and acquisitions will be a theme for pharma and biotech. With Takeda Pharmaceutical’s (4502.Japan) deal to buy Shire (SHPG), Leerink's Geoffrey Porges takes a look at what other deals could come to fruition. If companies chose to borrow to make acquisitions, that wouldn't be a problem either, he argues, as the group could collectively borrow another $460 billion if the industry returned to its peak leverage ratios, and the biggest companies could easily absorb any acquisitions with little debt worries, especially with synergies.
- InvestorPlace•3 hours ago
3 Big Pharma Stocks with Huge Future Growth Potential
You might not be aware of it, but big pharma stocks have gone through a difficult period for many years. A lot of the big drugs at the big pharma stocks went off patent, and the revenue for some of the big pharma stocks has fallen off as a result. Some of the big pharma stocks were able to replace that revenue and some weren’t.
- CNBC•4 hours ago
Stocks making the biggest moves premarket: BBY, MDT, HRL, MCK, DEO, FOXA, F, GM & more
The electronics retailer earned an adjusted 82 cents per share for the first quarter , 8 cents a share above estimates, with revenue also exceeding forecasts. Best Buy reported a comparable store sales increase of 7.1 percent, well above the consensus Thomson Reuters forecast of a 3.0 percent increase. Medtronic MDT – The medical device maker's quarterly numbers came in 3 cents above estimates at an adjusted $1.42 per share, with revenue also above Street forecasts.
- ACCESSWIRE•5 hours ago
Ex-Dividend Alert: Johnson & Johnson Boosted its Dividend by 7.1%; Will Trade Ex-Dividend on May 25, 2018
LONDON, UK / ACCESSWIRE / May 24, 2018 / Active-Investors has a free review on Johnson & Johnson (NYSE: JNJ) following the Company's announcement that it will begin trading ex-dividend on May 25, 2018. Active-Investors has initiated due-diligence on this dividend stock. If your portfolio includes dividend stocks, you have come to the right place for timely information.
Reuters•17 hours agoJ&J hit with $21.7 million verdict in another talc asbestos cancer case
Johnson & Johnson (JNJ.N) and its talc suppliers on Wednesday were hit with a $21.7 million jury verdict in a lawsuit by a woman who said she developed cancer after being exposed to asbestos in the company's Baby Powder. The verdict by a Los Angeles jury came down in the case of 68-year-old Joanne Anderson, who was diagnosed with mesothelioma, a form of cancer closely linked to asbestos exposure, and marked the second trial loss for J&J over similar allegations. Of the $21.7 million the jury awarded in compensatory damages, J&J was assigned 67 percent, with the rest distributed among other defendants.
- Reuters•17 hours ago
J&J hit with $21.7 million verdict in another talc asbestos cancer case
Johnson & Johnson (JNJ.N) and its talc suppliers on Wednesday were hit with a $21.7 million (£16.2 million) jury verdict in a lawsuit by a woman who said she developed cancer after being exposed to asbestos in the company's Baby Powder. The verdict by a Los Angeles jury came down in the case of 68-year-old Joanne Anderson, who was diagnosed with mesothelioma, a form of cancer closely linked to asbestos exposure, and marked the second trial loss for J&J over similar allegations. Of the $21.7 million the jury awarded in compensatory damages, J&J was assigned 67 percent, with the rest distributed among other defendants.
- Bloomberg•19 hours ago
J&J Loses Second Talc-Asbestos Trial and Damages May Grow
Johnson & Johnson lost a second trial linking baby powder use to deadly asbestos cancer and jurors must next decide whether to punish the company on top of their award of $21.7 million in damages. Jurors in state court in California concluded Wednesday J&J was liable for Joanne Anderson’s mesothelioma and awarded the 68-year-old compensatory damages. It’s the second jury in less than two months to conclude J&J sold its iconic baby powder knowing it contained at least trace amounts of asbestos and posed a cancer risk to users.
- Motley Fool•23 hours ago
Why Geron Corporation Stock Is Heating Up
Geron's stock is blasting higher this week, but the exact reason isn't clear.
- Zacks•yesterday
Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis
Eli Lilly (LLY) gets FDA approval for label expansion of its psoriasis injection Taltz to include data for psoriasis involving the genital area.
Reuters•yesterdayWhy the world needs more than one Ebola vaccine
LONDON (Reuters) - - In the life-and-death race to make the first effective vaccine against Ebola, one company - Merck (MRK.N) - seems bound to win. Immunisations with Merck's VSV EBOV experimental shot began in Congo this week - a big moment in a 40-year fight against a disease that until now could only be tackled by isolation and strict hygiene. Having this vaccine means the world is better placed now than it was in 2014-2016, when the haemorrhagic fever killed more than 11,300 people in history's worst Ebola outbreak in West Africa.
- Zacks•yesterday
Is Fidelity Dividend ETF for Rising Rates (FDRR) a Hot ETF Right Now?
Smart Beta ETF report for FDRR
Yahoo Finance Video•2 hours agoWillams-Sonoma, Deutsche Bank and Johnson & Johnson are the Yahoo Finance charts of the day.
Let's check out the Yahoo Finance charts of the day. Willams- Sonoma (WSM): Shares are surge in early trade, at around 12.61%. The retailer reported first-quarter earnings and revenue that easily beat analysts' expectations. Deutsche Bank (DB): Shares dive here, 6.87%. The bank said it will trim it's global staff from 97,000 to 90,000 as the new CEO looks to cut expenses and restore profitability at Germany's largest bank. Johnson & Johnson (JNJ): Shares down here, at around .74%. J&J and its talc suppliers were hit with a $21.7 million jury verdict in a case involving a woman who said she developed cancer after being exposed to asbestos in the company's baby powder products. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.
